Polycystic ovary syndrome: important underrecognised cardiometabolic risk factor in reproductive-age women

Review, Article English OPEN
Dinka Pavicic Baldani; Lana Skrgatic; Roya Ougouag;
(2015)

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder amongst women of reproductive age. Although PCOS is diagnosed exclusively based on reproductive criteria, it is also a metabolic disorder. Insulin resistance, impaired glucose tolerance, type 2 diabe... View more
  • References (177)
    177 references, page 1 of 18

    [1] A. Bargiota and E. Diamanti-Kandarakis, “The eefcts of old, new and emerging medicines on metabolic aberrations in PCOS,” eThrapeutic Advances in Endocrinology and Metabolism , vol. 3, no. 1, pp. 27-47, 2012.

    [2] W. A. March, V. M. Moore, K. J. Willson, D. I. W. Phillips, R. J. Norman, and M. J. Davies, “eTh prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria,” Human Reproduction, vol. 25, no. 2, pp. 544-551, 2010.

    [3] J. A. Tomlinson, J. H. Pinkney, P. Evans, A. Millward, and E. Stenhouse, “Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome,” British Journal of Diabetes and Vascular Disease, vol. 13, no. 3, pp. 115-123, 2013.

    [4] L. K. Hofman and D. A. Ehrmann, “Cardiometabolic features of polycystic ovary syndrome,” Nature Clinical Practice Endocrinology & Metabolism, vol. 4, no. 4, pp. 215-222, 2008.

    [5] H. Teede, A. Deeks, and L. Moran, “Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan,” BMC Medicine, vol. 8, article 41, 2010.

    [6] E. Diamanti-Kandarakis and A. Dunaif, “Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications,” Endocrine Reviews, vol. 33, no. 6, pp. 981-1030, 2012.

    [7] L. J. Moran, M. L. Misso, R. A. Wild, and R. J. Norman, “Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis,” Human Reproduction Update, vol. 16, no. 4, pp. 347-363, 2010.

    [8] H. S. Randeva, B. K. Tan, M. O. Weickert et al., “Cardiometabolic aspects of the polycystic ovary syndrome,” Endocrine Reviews, vol. 33, no. 5, pp. 812-841, 2012.

    [9] F. Orio Jr., S. Palomba, T. Cascella et al., “Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4588-4593, 2004.

    [10] H. F. Escobar-Morreale, M. Luque-Ram´ırez, and F. Gonza´lez, “Circulating inaflmmatory markers in polycystic ovary syndrome: a systematic review and metaanalysis,” Fertility and Sterility, vol. 95, no. 3, pp. 1048.e2-1058.e2, 2011.

  • Related Organizations (2)
  • Metrics
Share - Bookmark